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Abstract 
Although most people today assume that evidence-based medicine has had a significant 
effect on improving certain aspects of health care quality, it is also clear that evidence-based 
medicine has yet to reach its full potential and still has quite a bit of room to grow. 
Unfortunately, the principle that served as the foundation of evidence-based medicine has not 
lived up to its original promise. In this paper, I examine guideline implementation programs with 
the intention of identifying the underlying characteristics that contribute to their success and 
exploring ways in which these values can be adapted in the future. First, I briefly discuss the 
historical context of evidence-based medicine, its original intention, and how that perception has 
changed over time. This discussion presents the three-step process of practicing evidence-
based medicine: developing systematic reviews; creating clinical practice guidelines; and 
implementing those guidelines in clinical practice. It addresses the barriers impeding the 
process and shows how guideline implementation programs dismantle those obstacles. 
Second, the paper delineates the treatment gap between best practice defined by 
research evidence and actual clinical practice and it illustrates the gap by looking specifically at 
beta-blocker use in the secondary prevention of myocardial infarction. The analysis shows that 
guideline implementation programs targeted to increase the use of beta-blockers in myocardial 
infarction patients appear to be related to more evidence-based practice and, through that 
improved practice, on better health outcomes. 
The literature suggests that general data feedback, clinical care coordinators, and 
clinical education are associated with successful guideline implementation programs. Programs 
designed to reach multiple hospitals benefit from simultaneous use of a wide variety of 
implementation supports. Smaller programs, on the other hand, benefit from goal-directed 
designs focusing on a few key components tailored to their particular needs. The paper 
concludes with implications for research, ongoing program development, future policymaking, 
and the success of evidence-based medicine in general. 
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Introduction 
Evidence-based medicine first began entering the consciousness of the medical 
community in the early 1990s, and with it came the promise that this approach would elevate 
the quality of health care delivered to patients. From its inception, evidence-based medicine was 
designed to improve patient outcomes by helping physicians integrate the best available 
medical evidence into their clinical decision-making.'· 2 In one of the most cited definitions, 
Sackett et al. described evidence-based medicine as "the conscientious, explicit, and judicious 
use of current best evidence in making decisions about the care of individual patients". 3 Jnitially 
this concept met with a great deal of resistance from the medical community: it was viewed by 
many to be a threat to physician autonomy and a recipe for "cookbook medicine". 
Recently researchers have started using the term "evidence-based practice" instead of 
"evidence-based medicine." Evidence-based practice is defined as the "integration of best 
research evidence with clinical expertise and patient values" 4 Although many people use the 
two terms interchangeably, evidence-based practice explicitly takes into consideration the 
patient's and physician's shared responsibility for decision-making, and evidence-based practice 
does not carry the same taint of being "cookbook medicine" as did evidence-based medicine. 
To avoid any confusion, this paper will primarily use evidence-based practice to refer to the 
translation of research into practice, and will only refer to evidence-based medicine when 
discussing the history of its terminology. In the past 15 years the perception of evidence-based 
practice has changed considerably and many clinicians have now come to embrace the idea 
evidence from clinical research can and should be a major component in clinical decision-
making.' 
Although most people today assume that evidence-based practice has had a significant 
effect on improving certain aspects of health care quality, it is also clear that evidence-based 
practice has yet to reach its full potential and still has quite a bit of room to grow. Unfortunately, 
the principle that served as the foundation of evidence-based practice has not lived up to its 
original promise 2 On the one hand, evidence-based practice has been instrumental in changing 
the way medical research is conducted, assembled, and analyzed. In the past decade alone, 
significant advancements in the organization of medical research can be seen in the forms of 
systematic reviews and clinical practice guidelines (CPGs), and evidence-based practice is 
institutionalized in infrastructures of various types, including the all-volunteer, public private 
hybrid Cochrane Collaboration and the Evidence Based Practice Centers sponsored by the 
Agency for Healthcare Research and Quality (AHRQ), signifying the place of evidence-based 
practice on the public agenda .. 
On the other hand, the effect evidence-based medicine has had on how medicine is 
practiced in the everyday clinical setting has not been nearly as profound 6 The ability of 
research evidence, assembled in the form of systematic reviews and CPGs, to inform clinical 
decision-making has proven to be more difficult than early proponents hoped. 5 The literature on 
translation of research into practice (commonly known in health services research circles as 
"TRIP") continues to uncover substantial gaps between the best practices supported by 
research evidence and the way medicine is practiced in the real-world setting.'· 5· 6 Clearly, we 
must remain focused on fulfilling the original intentions of evidence-based practice and 
maximizing its influence on health care outcomes if evidence-based medicine is to live up to its 
promise. 
CPGs, or any other evidence-based practice tool for that matter, are not designed to be 
applied in every patient. As stated before, evidence is not the only element of decision-making, 
and not all patients can be expected fit the criteria specified by guideline recommendations. 
Therefore, even with a strong evidence base, CPGs will have some limitations to their use. 
Although CPGs can be treated as standard of care, their role in relieving or stimulating liability 
concerns is a contested one. In light of these considerations, the goal should be to maximize the 
use of CPGs, not to universalize them. 
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The goal of this paper is to elucidate some of the reasons why evidence-based practice 
has failed to realize its full potential by investigating how guideline implementation programs can 
be more effective at translating evidence into improvement in patient care. This paper will use 
programs that seek to implement widely agreed-upon guidelines for prescribing beta-blockers in 
patients with a history of myocardial infarction (MI) as an example of the challenges facing those 
who wish to institutionalize evidence-based practice. The evidence for post-MI beta blocker 
use is strong and non-controversial, and the intervention - providing a prescription most often at 
the time of discharge from the hospital- is not difficult. Yet prescribing beta blockers to 
appropriate patient candidates is still not the norm. If such an uncontroversial and relatively 
easy manifestation of evidence-based medicine is not routine, more difficult implementations will 
face even greater challenges. I will use the example of post-MI prescription of beta-blockers to 
identify the specific program components that are indicative of successful guideline 
implementation, and suggest ways that factors associated with success can be adapted to apply 
to other settings for the ultimate purpose of improving the effectiveness of evidence-based 
practice. 
Subject Relevance 
The study of successful guideline implementation programs is important for several key 
reasons. The first and perhaps most important public health contribution is the degree to which 
improving guideline implementation and extending the reach of evidence-based practice can 
improve health care quality on a population level. Second, guideline implementation programs 
have yet to be developed or studied to the same degree as have the methods associated with 
developing systematic reviews or CPGs and yet, without an understanding of best methods of 
implementing these tools of evidence-based practice, the tools themselves have limited utility. 
Finally, an understanding of guideline implementation is important because the provider 
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community must be able to "build implementation in" to its plans for translating research into 
practice and policy change if the translation is to succeed. 
It is important to recognize that evidence-based practice cannot be the answer to all 
clinical problems. Research evidence is only one of several factors taken into consideration 
when delivering care. Clinicians must also take into account the values of their patients, the 
constraints of their health care system, and their own expertise when making clinical decisions 
for their patients. Apart from the importance of other factors, the evidence base is limited. Few 
clinical practices in medicine are supported by strong empirical evidence. The British Medical 
Journal of Clinical Evidence, for example, concluded that only 15% of clinical practice is 
supported by "strong" evidence-' Ethical, financial, and practical limits mean that strong 
evidence can never be expected to support all clinical situations. 
Even in situations where research evidence is applicable patients often do not receive 
evidence-based care6 McGlynn, Asch, Adams et al. found, in a noted study, that only 59% of 
patients received recommended care 8 Studies continue to demonstrate that scientific evidence 
is not being used to its full potential, with treatment gaps- discrepancy between what the 
evidence suggests and what real-world practice is -- common. 1· 5• 6 Despite all the attention 
devoted to the advancement of evidence-based medicine in recent years, the health care 
system is still having difficulty translating evidence into clinical practice. 
Quality of care can be improved by the incorporation of the best available evidence into 
practice. Persistent treatment gaps suggest that not nearly enough resources have been 
devoted to seeing that the evidence is translated into practice. Guideline implementation 
programs help physicians incorporate guidelines into their real-world practice environments. 
Further, the development of systematic reviews and CPGs absorbs considerable time, money, 
and energy. When these tools are not used, the resources poured into their creation may be 
wasted. The emphasis on guideline implementation is relatively new, but critical analyses of 
what succeeds and fails in guideline implementation is appropriate. Critical analyses of the 
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effectiveness of evidence-based practice also have particular relevance for future policy 
change. 
Background and rationale 
Systematic reviews and CPGs have emerged as the primary tools to deliver evidence-
based medicine.2· 5 Systematic reviews are "concise summaries of the best available evidence 
that address sharply defined clinical questions". 9 They assess the strength of the available 
literature and help practitioners identify the evidence that is most relevant to the treatment of 
their patients. Over 2 million articles are published each year and systematic reviews are one of 
the resources available to help clinicians manage the overwhelming amount of new research. 10 
It is rare that a single study is robust enough to provide clinically meaningful knowledge with any 
kind of certainty. Systematic reviews are advantageous because, by pooling the results of many 
different studies, they help determine if consistencies exist among the literature-" They also help 
decrease biases and improve the reliability of the results by compiling raw data. 10· 11 
Recently, the science of developing systematic reviews has also become an increasingly 
important area of study, as epidemiologists have searched for ways to improve current research 
methods. 5 Programs such as the Evidence-based Working Group and the Cochrane 
Collaboration have been instrumental in improving the development of systematic reviews. The 
Evidence-based Working Group has created user guides to aid in the critical appraisal, grading, 
and interpretation of primary studies. 11 The Cochrane Collaboration has been instrumental in 
the preparation, maintenance, and dissemination of systematic reviews.''· 12 These initiatives 
represent a remarkable advance in the process of assembling, evaluating, and interpreting 
medical research. The underlying hope supporting the time and energy spent by the members 
of these groups is that improving the quality of evidence will lead directly to improvements in the 
quality of care. 
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The second evidence-based medicine implementation tool, and the logical extension of 
the systematic review, is the CPG. The Institute of Medicine defines a clinical practice guideline 
as a "systematically developed statement to assist practitioner and patient decisions about 
appropriate health care for specific clinical circumstances". 13 The process of creating CPGs 
begins with evidence gathering in the form of systematic reviews; the next step is that of using 
the review, enhanced by "grading" of the literature and modulated with expert clinical judgment, 
to make recommendations about clinical practice. Theoretically, CPGs, when used properly, 
will improve quality, reduce inappropriate variation in care, and serve as valuable education 
tools for physicians and patients. 14 Guideline implementation programs are intended to make it 
easier for clinicians to deploy the resulting tool -the CPG- in real world settings of care and 
apply this research evidence in their everyday practice. 
Systematic reviews and CPGs are the foundations of evidence-based medicine, but they 
are only part of story. CPGs are not meant to be a one-size-fits-all dictate. They are meant to 
serve as recommendations that clinicians and patients can factor into their decision-making 
Only recently have concerted efforts to assist practitioners with adapting evidence found in 
systematic reviews and CPGs become more common. These efforts have led to the 
development of several guideline implementation programs focused on making sure that 
scientific evidence actually reaches the patient. Improving the translation of the best research 
evidence into clinical practice is paramount in the struggle to improve quality of care. 
Paper Outline 
In this paper, I examine guideline implementation programs with the intention of 
identifying the underlying characteristics that contribute to their success and exploring ways in 
which these values can be adapted in the future. First, I discuss the historical context of 
evidence-based medicine, its original intention, and how that perception has changed over time. 
I examine the three-step process of evidence-based practice: developing systematic reviews; 
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creating CPGs; and implementing those guidelines in clinical practice. I discuss the barriers that 
impede each step of the process and show how guideline implementation programs help 
dismantle those obstacles. 
Second, this paper sheds light on the treatment gap between best practice defined by 
research evidence and actual clinical practice. I illustrate the gap with a case study of beta-
blocker use in the secondary prevention of myocardial infarction. In particular, I investigate 
whether guideline implementation programs targeted toward increased prescribing of beta-
blockers following myocardial infarction in appropriate patients on prescribing and, via the 
provider's changed prescribing behavior, on health outcomes. 
Third, I more fully describe the methods and results of this study and conclude by 
addressing some of the implications of these results for future research on guideline 
implementation, for ongoing program development, future policymaking, and the success of 
evidence-based medicine in general. 
Evidence-Based Medicine: A Historical Perspective 
History 
Before diving headfirst into the study of guideline implementation programs, it is 
important to take a step back and look at evidence-based medicine from a historical 
perspective. Understanding the historical context of evidence-based medicine and how it has 
evolved over time is essential for three reasons. First, the history of evidence-based medicine 
provides a wealth of background knowledge that illuminates the current process of generating, 
assembling, and analyzing evidence. Second, when conducting policy analysis, the historical 
context is often a critical, determinative variable in the analysis; policies are often understood as 
the result of path dependence, or the dependence of current policy arrangements on choices 
made- and not made- earlier.15 Third, implementing meaningful policy change in the future 
depends on an understanding of policy origins and context, just as analysis of current policy 
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must resort to its history. Understanding the original intention of evidence-based medicine, its 
effect on the field of medicine, and how it has changed over time is the only way to ensure that 
we do not repeat mistakes of the past. 
The term "evidence-based medicine" first appeared in the medical literature in the early 
1990s but one can trace its roots back to the early work of Florence Nightingale and Ernest 
Godman.16.18 In the mid-19th century, Florence Nightingale pioneered the systems approach to 
health care research and purposefully gathered, analyzed, and used evidence to determine the 
best treatment strategies for patients. She routinely monitored the progress of her hospitalized 
patients and kept extensive records of their health outcomes. Her constant data collection 
enabled her quickly to identify ineffective or harmful treatments and use that information to 
improve the processes of careH 
At the start of the 20th century Ernest Godman added to the ideas originated by 
Nightingale. He believed that physicians should regulate themselves by monitoring the clinical 
outcomes of all their patients, analyzing treatment failures, and making the necessary changes 
to improve their clinical practice. He was also an advocate for making these records of patient 
outcomes available to the public to serve as a motivation for what we would now call quality 
improvement. The common thread between Nightingale and Godman is that they both 
appreciated the role of research evidence in changing the processes of care. They also 
recognized that scientific inquiry into a treatment's effectiveness was just as important as the 
treatment itself. 18 
After World War II, the field of medicine experienced a surge in therapeutic options due 
in large part to the acceptance of germ theory, the discovery of antibiotics, and the development 
of new treatment procedures.'· 19 Optimism within the medical community grew as physicians 
were able to provide a greater variety of treatment options to their patients. Physicians began to 
move from simply managing a patent's condition to actually being able to treat it. 19 This 
transition to more active medicine occurred at a time when the field of medicine had no system 
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set in place to study the effectiveness or potential harms of their new treatments." The increase 
in therapeutic options proved to be a double-edged sword for the health care system. On the 
one hand, it afforded physicians the opportunity to offer their patients treatment options 
heretofore unavailable. On the other hand, medicine developed in comparatively unchecked 
ways, in an environment where many new, and potentially harmful, treatments could be widely 
disseminated to patients without proof of their effectiveness. 
In the 1960s, randomized control trials began increasing in popularity as medical 
researchers sought to provide evidence of efficacy for the new treatments they were providing 
and reduce the occurrence of treatment disasters.16 Practitioners and researchers at that time 
were reminded of the value of scientific inquiry and realized that without proper investigation, 
many of the new diagnostic and therapeutic procedures could be causing their patients more 
harm than good. 1 The renewed interest in scientific inquiry led to a surge in the amount of 
clinical research being conducted, particularly randomized control trials. During the 1970s, many 
of the randomized control trials were primarily focused on assessing the effectiveness of new 
technological advancements.16 It would take both time and evidence of compromised health 
care quality before the focus of research would shift to the exploration of health outcomes. 
One of the first studies to reveal questionable effectiveness and appropriateness amidst 
rising cost was the small area variation work of Wennberg and Grittelsohn first published in 
1982.20 Their study of the surgeons in New England revealed widespread geographic variation 
in the rates of clinical practice. Although variation by itself is not a threat to health care quality, 
the clinical practice discrepancies found by Wennberg and Gittelsohn are significant because 
they could not be explained by population differences, they often resulted in more expensive 
health care, and yet did not give rise to significantly better health outcomes20 The most 
troubling implication of their findings was that the variation in clinical practice was not associated 
with factors such as need for care, but instead it had more to do with factors such as geography, 
socioeconomic status, local practice preferences, ethnicity, and gender. 21 Not only did they find 
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that this variation was unnecessary and unwarranted, but it often compromised health care 
quality, cost, and safety of the patients involved. 
Subsequent studies revealed that inappropriate clinical variation was not specific to the 
New England region. In fact, Wennberg's and Gittelsohn's results proved to be indicative of a 
much larger problem. 20 Unwarranted variation has been demonstrated in a variety of clinical 
practices and throughout the United States. 22'24 Evidence-based medicine, in theory, should 
help eliminate inappropriate variation and promote higher standards of practice in clinical 
medicine. This is not to say that evidence should eliminate all clinical variation; it is, instead, to 
say that variation must be based on the needs and values of patients rather than random, 
unjustified factors such as local practice precedents. 
Wennberg's and Grittelsohn's revelation that decision-making strategies might be 
compromising health care quality helped usher in the modern movement of evidence-based 
medicine. It advocated for the idea that the dissemination and implementation of strong medical 
evidence on a broad scale could be an effective means of improving the quality of health care 
delivered to patients. 25 Evidence-based medicine has sought to improve health care quality by 
shifting the basis of clinical decision-making from a model based solely on factors unique to the 
patient and physician to one with a stronger scientific foundation that aims to integrate individual 
expertise with external evidence. 2· 3 Wennberg and Grittelsohn suggested that incorporating 
medical literature into clinical decision-making would create uniformity in some aspects of care 
without eradicating either clinical judgment or the need to tailor care to individual patient needs. 
Dramatically rising health care costs and growing evidence of inappropriate care are 
some of the reasons why randomized control trials begin evaluating health related outcomes. 16 
The medical research community began evaluating patient outcomes in an effort to understand 
the effect of unjustified variations in medical practice on health care quality and cost!' As a 
means of helping physicians manage the growing volume of randomized control trials, 
systematic review articles became a staple in medical literature. 16 But as more studies were 
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conducted, physicians found the process of incorporating research evidence into clinical 
practice increasingly difficult.5 Systematic reviews made it easier for clinicians to find the highest 
quality research in an orderly, transparent manner and then apply that knowledge to their 
clinical decisions. 
CPGs soon developed out of the same need that had called for systematic reviews. 26 
Medical professional organizations and other institutions began making concise clinical 
recommendations based on evidence compiled from systematic reviews. These CPGs were 
developed to provide clinicians with management strategies rooted in evidence but capable of 
adaptation to patient values and clinical expertise. 
Current state of evidence-based medicine 
In recent years, the medical community has changed the way it thinks about the role of 
evidence in clinical medicine.' Evidence-based medicine is no longer regarded as the panacea 
for the entire health care system or feared as a destroyer of individual physician autonomy and 
judgment. Instead, it is viewed as one of many tools used in the decision-making process.' The 
focus has slowly shifted from evidence-based medicine to evidence-based practice. Evidence 
base practice is defined as "the integration of the best research evidence with clinical expertise 
and patient values". Evidence-based practice differs from evidence-based medicine because it 
is rooted in the principle of shared decision making and stresses the importance of both patients 
and physicians in health care decision-making. 
Over the years the evidence-based approach has won over much of the medical 
community26 In the process, evidence-based practice has also shaped the way many 
physicians approach clinical medicine. Although the widespread acceptance of evidence-based 
practice has been a relatively recent movement, the idea that clinical practice should be rooted 
in scientific evidence has been several years- or even a century, to give Nightingale and 
Godman their due -- in the making. 1• 16 In the process of adopting this new way of thinking, the 
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medical community also changed its ideas about what it considers high quality health care and 
the best way to achieve it in clinical practice.' 
In the past 15 years, many organization and programs have been developed in an effort 
to help implement evidence-based medicine. The Cochrane Collaboration is an international 
not-for-profit organization whose goal is to improve informed decision-making by preparing, 
maintaining, and ensuring the accessibility of systematic reviews. 12 Efforts such as the quality of 
reports of meta-analysis (QUOROM) statement have also attempted to standardize the 
presentation of evidence by providing explicit instructions to physicians and researchers on how 
to report systematic reviews and meta-analyses26· 27 
The Agency for Healthcare Research and Quality (AHRQ), the Department of Health 
and Human Services entity charged with vigilance for the nation's health care quality, and the 
American Medical Association (AMA) created the National Guideline Clearinghouse to help the 
medical community to manage the growing number of clinical guidelines being produced. The 
National Guideline Clearinghouse provides executive summaries and the full guidelines for a 
very large number of conditions and combinations of conditions. The Clearinghouse's mission 
is to further the dissemination and implementation of CPGs. 
In 1997 AHRQ, then known as the Agency for Health Care Policy and Research, 
commissioned the development of 12 evidence-based practice centers (EPC). The purpose of 
the EPCs is to "promote evidence-based practice in everyday care". The 12 EPCs set out to 
improve the quality, effectiveness, and appropriateness of health care by providing evidence 
reports for topics relevant to clinical medicine. 28 
Each of these examples demonstrates what some have referred to as the current "trend 
to evidence". 26 As the medical community has become more comfortable with the approaches of 
evidence-based medicine, many have expended effort to help put the approach into action. The 
next step in the goal of implementing evidence-based practice is to analyze the effectiveness of 
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our current efforts to implement guidelines and to identify the areas where there is room for 
improvement. 
Evidence-Based Medicine: The Process and the Barriers 
Generating systematic reviews 
The development of systematic reviews is a multi-step process posing difficulties at each 
step. 29 Systematic reviews' first steps are framing a focused clinical question (driven by 
intellectual as well as practical needs, since an overwhelming literature can be managed only by 
limiting and targeting the clinical question on which the literature is brought to bear), and 
identifying the appropriate literature to review29 The next steps are reviewing the literature (itself 
a significant task), assessing the quality of the literature using a validated grading system, and 
generating a comprehensive summary of the literature29 The final step is the interpretation of 
findings and discussion of the clinical meaning of the systematic review results. 2' 
At each step of the process, potential barriers impede the creation of good systematic 
review. One of the main review challenges is the many questions that could potentially provide 
valuable clinical information but cannot be answered because of a lack of evidence. Deciding 
which literature databases to use and determining which combination of medical subject 
headings (MeSH) will capture an acceptably high proportion of relevant articles is also 
problematic. Finding appropriately rigorous and yet usable tools for grading the quality of the 
evidence is another barrier to the development of good systematic reviews. Lohr and her 
colleagues conducted an analysis of the grading systems most commonly used to assess the 
quality of research articles and found that out of 121 grading systems they evaluated, only 19 
met the scientific standards necessary to analyze the quality of evidence effectively. 26 Finally, 
the actual process of the review is never as straightforward or linear as these clear steps 
suggest. Systematic reviews are challenging. 
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Generating clinical practice guidelines 
Generating a guideline means formulating and limiting the clinical question at the heat of 
the guideline, analyzing the pertinent evidence (most often meaning conducting a systematic 
review), using a combination of evidence, clinical experience, and expert consensus to make 
evidence-based recommendations about clinical practice, and then making those 
recommendations public. Various organizations and institutions have begun developing CPGs 
to suit their specific needs and unique patient populations. The proliferation of guidelines is 
evident in the hundreds of guidelines (many medical professional associations, academies, and 
colleges post over 100 guidelines each) maintained by the National Guideline Clearinghouse-"0 
One of the problems with creating guidelines is that they are only as good as the 
evidence on which they are based. Guidelines based on limited data or poor quality studies do 
the evidence-based medicine movement a disservice. In addition, CPGs should take into 
account real-world factors such as cost-effectiveness and clinical significance. For example, 
some populations are underrepresented in the primary studies and, as a result, physicians may 
be hesitant to use guidelines in their treatment of members of these populations. CPGs that 
cannot be made relevant to clinicians' needs are much less likely to be used .. 
Evidence-based practice: putting guidelines into practice 
CPGs do not have the force of law; they must be adopted voluntarily. Thus guideline 
implementation programs are designed to support the tailoring, and embracing, of guidelines at 
the level of the individual health system. Guideline implementation programs can be developed 
by any group with a vested interest in trying to use evidence-based medicine to improve care, 
from large organizations such as insurance companies and patient advocacy groups to smaller 
health care systems like community hospitals or private practices. The goal of these programs is 
to adapt the recommendations of CPGs to suit different health care systems and different 
patient populations. 
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The barriers to guideline implementation can be divided into two broad classes of 
physician factors and system factors. Physician factors include physician awareness and 
willingness to adopt guidelines. 31 Before guidelines are implemented, health care professional 
must be aware of the recommendations and must be willing to implement them, even- or 
especially- when they require a change in practice. System factors include environmental or 
organizational factors such as financial and structural limits, time constraints, and the desires of 
the patients. If guideline implementation programs are to be successful they must overcome the 
barriers posed by both sets of factors-"'· 32 
Example: Beta-Blocker Use in the Secondary Prevention of Myocardial Infarction 
Why myocardial infarction? 
Myocardial infarction (MI), commonly known as a heart attack, is defined as a reduction 
of blood supply to the heart that results from a blockage of one or more of the coronary arteries 
and ultimately leads to damage to or death of heart tissue. 33 While myocardial infarction is 
classified as a disease on its own, it is also part of a broader umbrella condition known as 
coronary heart disease (CHD). Coronary heart disease is a spectrum of diseases that result in 
compromised blood flow to the heart. In its mildest form CHD is asymptomatic, but in its most 
severe form patients may experience a myocardial infarction or death. 
Myocardial infarction is a disease that lends itself easily to the study of guideline 
development and implementation for several important reasons. First, it carries a high burden of 
disease. Myocardial infarction is a major health concern in United States because it is a 
significant cause of morbidity and mortality. 34 Currently 15.7 million people in the United States 
have been diagnosed with CHD. 35 In this year alone an estimated 1.2 million people will have a 
myocardial infarction. 35 Of these, 700,000 are expected to be new infarctions and 500,000 will 
be recurrent myocardial infarctions. 34 
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Coronary heart disease is the leading cause of death in the United States and accounts 
for approximately 654,000 deaths each year. Each year approximately 38% of all the people 
who experience an Ml will die from it, for an approximate total of 221,000 Ml deaths each year. 35 
Having the evidence that a significant number of these deaths could be prevented by 
implementing guidelines makes guideline implementation an important public health concern. 
The second reason to use this example is that Ml management has a well-established 
and evidence-based standard of care. The appropriate treatment of patients with myocardial 
infarction has been the target of CPGs for years. Both the American Heart Association (AHA) 
and the American College of Cardiology (ACC) have been leaders in the creation of guidelines 
for Ml management, having released joint guidelines on the management of Ml since 1999. As a 
testament to the general acceptance of these guidelines, the Joint Commission and Centers for 
Medicaid and Medicare Services (CMS) have adopted many of the recommendations as quality 
indicators. 36 
In the joint AHA /ACC guidelines issued for the secondary prevention of myocardial 
infarction, the highest recommendation (Class 1) was given to the recommendation that 
physicians start post-MI patients on beta-blockers and to continue their use indefinitely in "all 
patients who have had myocardial infarction, acute coronary syndrome, or left ventricular 
dysfunction with or without heart failure symptoms, unless contraindicated". 37 
The third reason why myocardial infarction is such a suitable topic for the study of 
guideline implementation programs is the strong evidence that a treatment gap exists. 34· 38• 39 
The recommendation to start and continue beta-blockers is clear, simple, and supported by high 
quality evidence. Following the guideline will result in better outcomes for post-MI patients. 
Why should a gap between the recommendation and actual practice persist? Understanding 
the gap, and successful strategies for closing the gap, should produce findings that can be 
applied to other guideline implementation efforts. 
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Why Beta-blockers? 
Of all of the guideline recommendations available for the treatment of myocardial 
infarction, the underuse of beta-blockers is one of the clearest cases of unwarranted failure to 
use the evidence. Since the late 1980s medical research has supported the long-term use of 
beta-blockers after myocardial infarction in order to reduce mortality and reinfarction. 6• 40 It is 
thought that beta-blockers decrease the workload of the heart by slowing the velocity of 
contracting and allowing the coronary vessels more time to fill. 34 From the first publication of the 
evidence 20 years ago to the present, the evidence has supported the use of beta-blockers for 
the secondary prevention of myocardial infarction.41 
Initial studies found that use of beta-blockers in post-myocardial infarction (post-MI) 
patients reduced mortality by 19-48% and decreased rates of reinfarction by as much as 28% 34· 
38 Phillips et al. found that if beta-blockers were prescribed to all first-MI survivors without 
contraindications for the next 20 years, 72,000 CHD deaths and 62,000 cases of Ml would be 
prevented. They also found savings of $18 million dollars and gains of 44,7000 life-years.41 
In addition to its health and cost benefits, beta-blocker use is a good case for testing the 
power of guideline implementation programs because it is an easy outcome to measure. Other 
very important quality indicators are much more difficult to measure. Beta-blocker prescriptions' 
comparative ease of measurement make them among the "low-hanging fruit" of quality 
improvement research, but this does not make studies of their use any less important. Indeed, 
to the degree that compliance with the beta-blocker recommendation is not only easy to do, but 
easy to measure, finding a treatment gap in this case should suggest the size of the challenge 
to practice evidence-based medicine. 
The treatment gap 
Despite evidence from countless systematic reviews and multiple evidence-based 
guidelines, beta-blockers are substantially underused in post-MI patients. 38• 39 The gap between 
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best evidence and every day practice first began gaining public attention in the mid-1990s. 34 It 
has been estimated that as many as 80% of patients who have a myocardial infarction should 
be prescribed long-term regimen of beta-blockers yet only 40% actually receive beta-blockers in 
the clinical setting. 38 
From the patient-centered perspective, the most important consequence of poor 
adherence to guidelines is the unnecessary mortality and morbidity. In an attempt to quantify the 
gap between best practice, defined by research, and everyday practice, Sim and Cummings 
conducted a sophisticated analysis of hospital discharge data to determine the number not 
prevented (NNP) by beta-blocker under-use.s The NNP is a numerical representation of the 
numbers of deaths that would have been prevented if patients had received the recommended 
therapy, which in this case was beta-blocker prescription after MI. Their calculations uncovered 
approximately 2995 U.S. patients annually who died in their first year post-MI and whose deaths 
would otherwise have been prevented had beta-blockers been prescribed. The ability to quantify 
the treatment gap is useful because it can so starkly illustrate the consequences of poor 
adherence to guidelines.6 
Bradford, Chen, and Krumholz examined economic effects of beta-blocker underuse and 
found three types of cost arising from poor adherence to guidelines. 34 Underuse of beta-
blockers is costly to the health care system because of the resulting unnecessary morbidity and 
mortality; it is also costly because underuse leads to more use of health care resources 
following the failure to engage in secondary prevention. Finally, they argued, beta-blocker 
underuse raised health care costs because post-MI patients who did not receive beta blockers 
were more likely to use other, more expensive, but less effective treatments. Their framework 




Before selecting the program evaluation articles that would be analyzed in this paper, I 
first had to design a comprehensive search strategy. My search strategy included picking the 
literature database, selecting a combination of search terms, and choosing the inclusion and 
exclusion criteria for accepting or rejecting articles. Time constraints, limited resources, and a 
desire to focus on U.S. studies of guideline implementation led to my choosing PubMed, the 
National Library of Medicine's massive biomedical literature archive. 
The most difficult part of finding the literature was selecting the appropriate search 
terms. PubMed can be searched with any key words, but the Medical Subject Headings (MeSH) 
system is the most sophisticated and detailed structure of search terms. The size and 
complexity of MeSH, however, and the fact that different MeSH terms may be assigned to 
substantially similar articles by different human coders, make identifying the best combination of 
search terms an uncertain task. To complicate matters further, many MeSH terms can seem 
redundant and overlapping. For example, articles that deal with beta-blockers may be coded as 
"adrenergic beta-antagonist", "anti-hypertensive agents", or "anti-arrhythmic agents" depending 
on coder judgment about the direction of the article. 
This search was additionally challenging because its focus was unlike that of other 
systematic reviews. The goal of this study was not to do a systematic review of all the evidence 
supporting beta-blocker use in myocardial infarction patients. Instead, the focus of my search 
was to identify the studies that have evaluated the health systems' attempts to create and 
sustain successful programs to assure these beta-blockers are prescribed. 
After consulting with experts in the field of library sciences, my advisors and I decided on 
which specific combination of MeSH terms would be the most effective at capturing all of the 
appropriate studies. The MeSH terms used included ("Adrenergic beta-Antagonists"[MAJR] OR 
"beta blockers"[tw]) AND ("Myocardial Infarction/drug therapy"[MAJR] OR "Myocardial 
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Infarction/prevention and controi"[MAJR]). Even with this precise combination of MeSH terms, 
the initial search still yielded 1083 articles. To get to the real focus of the search- evaluations of 
guideline implementation programs - I added the string "quality improvement OR quality 
assurance OR program evaluation" to the search algorithm. This additional string helped narrow 
the search to 79 articles. From these 79 articles, five fit the predetermined inclusion and 
exclusion criteria. I found the additional 10 articles by searching the "related articles" list of the 
first five retrieved articles. 
I also selected criteria for including or rejecting articles before conducting the literature 
search. All of the articles included in this analysis resulted from studies of randomized control 
trials or before-and-after analyses. I made this decision because it was important that all the 
articles include a comparison between the intervention -some technique or effort to improve 
guideline adherence-- and those who were not exposed to the intervention. In the randomized 
control trials, the intervention group had to have been compared to a control group receiving no 
intervention. In the before-after studies, beta-blocker prescription rates had to be measured both 
before and after the intervention (and, ideally, other control variables that might explain changed 
rates also needed to be measured). Some studies included a combination of these two study 
designs, often featuring groups of patients divided into control and intervention groups, with 
primary outcomes - beta-blocker prescription rates -- measured before and after 
implementation of a guideline adoption effort. Studies comparing one intervention to another 
without a reference control group were excluded from this analysis. 
I also limited the search to studies written in English and conducted on human 
participants. Each of the guideline implementation programs evaluated in these studies had to 
be targeted to patients with myocardial infarction. The outcome of interest had to include some 
measure of beta-blocker use or prescription on hospital discharge. It was important that the 
articles specifically investigate beta-blocker prescriptions on hospital discharge because 
including other types of beta-blocker use might have complicated the results. For example, if 
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outcomes such as beta-blocker prescription on admission, or use overall, were included, we 
would be unable to attribute real change to improved guideline adherence. 
It was also important that each published study was conducted in the United States. As 
mentioned above, since many of the policy issues associated with guideline implementation are 
unique to the United States health care system, I wanted the articles included in this study to 
reflect how guideline implementation works within the United States. Finally, all included 
studies had to have been published within the last 10 years (from May 151" 1997 to May 15, 
2007). The health care system is continuously evolving and a great deal can change in 10 
years. This analysis needed to reflect recent and current practice. Guideline implementation 
programs are also a relatively new phenomenon, so seeking literature from the last decade 
gave a good likelihood of capturing most of what has been done. 
The completed search yielded a total of 15 articles meeting all the inclusion and 
exclusion criteria, and I use all 15 articles in the following analysis. Although it is unlikely that 
all possible eligible articles were found with this search strategy, I believe that an acceptable 
percentage of these studies are analyzed here. The search strategy was comprehensive 
enough to generate a representative sample of program evaluation studies to evaluate and 
draw meaningful conclusions. A brief description of the final 15 articles analyzed in this study 
can be found in Table 2. 
Selecting variables 
After selecting the articles to be included, I had to design a set of variables to select the 
list of variables that would direct the coding of the resulting body of literature. The variables 
needed to provide clear ways of distinguishing the main components of each guideline 
implementation program and of cataloging apparently important sources of program success. 
chose coding variables based on studies that have investigated the hospital characteristics 
associated with high guideline adherence. Bradley, Herrin, and Mattera et al. published two 
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extensive surveys of various hospitals throughout the United States that identified hospital 
characteristics most highly correlated with beta-blocker prescription rates after acute myocardial 
infarction. 36• 42 The studies were conducted between 1996 and 1999 and the authors primarily 
looked at patient characteristics and hospital characteristics. Patient characteristics included 
factors such as the basic demographic information (age, gender, race and insurance status), 
clinical information, and laboratory values. Each of these characteristics were gathered from the 
medical records of hospitalized patients as part of the National Registry for Myocardial Infarction 
(NRMI). Hospital characteristics included geographic region, ownership type (government vs. 
for-profit vs. nonprofit), quality improvement interventions, average Ml volume, and the baseline 
rate of beta-blocker use. 36• 42 
Since the present study is focused primarily on the qualities of guideline implementation 
programs that are indicative of success, I extrapolated from the Bradley, Herrin, Matera et al. 
studies all the program characteristics that might lead to successful guideline implementation. 
Of all the patient and hospital characteristics they studied, only the variables that could possibly 
be components of a guideline implementation program were included. For example, the authors 
found that hospitals with clinical pathways, multidisciplinary teams, and general data feedback 
had higher rates of beta-blocker prescriptions than did hospitals without these features. 
Because it is possible for clinical pathways and multiple disciplinary teams to be components of 
a guideline implementation program, they were included in the list of variables. 
If a characteristic was negatively associated with beta-blocker use, I excluded it from my 
list of variables. For instance, the hospital survey found that physician-specific data feedback 
that targeted guideline non-adherent clinicians was negatively correlated with later compliance 
to beta-blocker guidelines; I did not include data feedback as a variable in the present study. It 
is important to note the difference between general data feedback and physician specific data 
feedback. General data feedback was feedback that did not single out specific clinicians but 
rather provided information about state or hospital guideline adherence rates. General feedback 
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has a positive correlation with program success and was therefore included in this list of 
variables. Physician-specific feedback only provided feedback information to clinicians who fell 
below a predetermined acceptable level of guideline adherence. This component was not 
associated with program success and was not included in this list of variables. 
As another example, Bradley, Herrin, and Matera et al. found that New England 
hospitals had higher rates of beta-blocker prescriptions. Geographic location, however, is not 
amenable to change, so I did not include it as a variable. Rather than where they are located, 
we need to know what it is about New England hospitals that makes them more guideline-
adherent, and ask whether those features can be exported to hospitals in other regions. The 
final list of variables used to code each study can be found in the Appendix. I evaluated each 
study to see how many of the variables were present in their programs, and whether the 
variables appeared to make a significant difference to guideline adherence. I then grouped the 
studies according to what combinations of variables provided the context for successful 
interventions. 
Critical Appraisal 
Assessing the internal and external validity of these studies must be critically examined 
in order to have a solid understanding of the results. Internal validity is a measure of how well as 
study measure what it intends to measure. The best way to assess internal validity is to 
evaluate the potential for selection, measurement, and confounding bias. External validity is a 
measure of how meaningful a study's results are to those not involved in the study. External 
validity is best assessed by evaluating the generalizability of the results. 
Selection bias 
Selection bias is a systematic error in the way participants are selected. When selection 
bias is not taken into consideration, study groups may end up being different from each other in 
ways other than the variable in question. If this occurs, the final results may be biased and it can 
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be difficult to interpret the findings. The randomization of participants into different study groups 
is one technique often used to reduce the potential for selection bias; however, in this analysis 
only 3 studies used this method to recruit their participants. 
Another way to evaluate the potential for selection bias is to compare the two groups on 
a series of basic characteristics to see if there are similarities. Whether or not a study uses the 
randomization, most studies will display group comparisons in a table format commonly known 
as a Table 1. This is done as a way to show that the two groups being studied are alike in every 
way other than the variable in question. Out of the 15 articles analyzed, a total of 11 provided a 
table that compared the two groups in terms of characteristics such as age, sex, and medical 
history. 
For the studies that included a Table 1, the study groups were found to be statistically 
similar on most characteristics indicating a decreased potential for selection bias. Although the 
studies that did not randomize their participants or provide a Table 1 do increase the potential 
for selection bias, its effect on the final results seems to be minimal. Because most of the 
studies included in this analysis had Table 1 comparisons that demonstrated similar study 
groups, it seems unlikely that selection bias would be affecting the results in any major way. 
Measurement bias 
Measurement bias occurs when there is a difference in the measurement or detection of 
a study's intended primary outcome. One way to reduce the potential for measurement bias is to 
blind or mask those in charge of making the observations so that they are not aware of which 
groups to which participants are assigned. This makes it less likely that outcome measurements 
will be differ depending on the study group. Unfortunately guideline implementation program 
evaluation studies there is no way to effectively blind people to the invention. 
Another way to reduce measurement bias is creating a priori definitions of the primary 
outcome before the study begins to ensure that outcome is measured equally in both groups. All 
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of the studies included in this analysis used pre-determined definitions of the primary outcome, 
which in this case was beta-blocker prescription. Most studies relied on medical records to 
ensure that the outcome was measured the same way. This likely helped reduce the potential 
for measurement bias. In terms of making sure that this 
Confounding bias 
Confounding bias is when another unknown variable distorts the association between 
the mean exposure and primary outcome. The same methods that are used to decrease 
selection bias are used to reduce the potential for selection bias are also used to decrease 
confounding bias. Randomization is the best way to account for all unknown variables and is 
one of the best methods of reducing confounding bias. Since very articles randomized their 
participants, confounding bias remains a concern when evaluating this quality of these studies. 
Unlike selection bias, there are an unlimited number of variables that could be contributing to 
confounding bias. When considering the internal validity of these studies, confounding bias is 
perhaps the biggest problem. 
Generalizability 
Generalizability is the extent to which findings from a particular study can be applied to 
the general population. Generalizability becomes a problem when the sample population is not 
representative of the larger target population. In the evaluation of guideline implementation 
programs, generalizability is particularly problematic because programs are often created for 
specific health care systems and are difficult to apply elsewhere. 
The two biggest threats to generalizability are randomization and volunteer bias. 
Sometimes in RCTs, the randomization process can control for so many variables that the 
sample population no longer resembles people in the general population. Thi was not a 
particular problem in this analysis because so few of the studies included used randomization. 
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When patients volunteer to participate in studies, subjects may have characteristics that 
are unlike the general population and therefore not capable of being readily applied. Volunteer 
participants may be more health conscious, more compliant, or different in other ways that do 
not make them representative of the general population. Volunteer bias is not an issue in this 
analysis because these studies used medical records as opposed to recruited participants. 
Recruitment into the study was determined primarily by the a priori Ml definition and 
inclusion criteria determined by each individual study. The clinical definition for Ml varied slight 
for different studies. The range of criteria for Ml included ICD-9 codes, cardiac biomarkers 
cutoffs, and medical record discharge diagnoses. While these definitions are likely to recruit 
slightly different types of Ml patients, all of these criteria are used in the real world and therefore 
generalizable to the general Ml population. 
While it can be argued that generalizability is not an issue in this analysis because not 
many studies used randomization or volunteered participants, application of these results 
should be done with caution. Because the types of guideline implementation programs vary so 
much, it is probably better to apply the results of these studies to programs of similar scope and 
size. 
Findings 
The literature search described above yielded 15 articles for analysis. The studies and 
their main features are presented in Table 1. The articles fell into one of three types of studies. 
The before-and-after design was used in 11 out of the15 articles and was the most common 
type. There was only one randomized control trial. The three remaining articles had some 
combination of randomized control trial and before-after study design. 
Overall, the studies demonstrated that guideline implementation programs are 
successful at increasing the percentage of post-MI patients who receive beta-blocker 
prescription. All but one of the studies included in this analysis demonstrated some 
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improvement in guideline adherence after an implementation intervention. Six studies 
demonstrated a statistically significant increase in beta-blocker prescriptions after program 
implementation. An additional eight studies demonstrated an increase in guideline 
implementation whose significance was either not significant or whose significance could not be 
determined. One study found a statistically insignificant decrease in beta-blocker use. 
The types of programs described by the studies in this analysis ranged from small, 
focused, hospital-based programs to large-scale interventions that involved hospitals in multiple 
states. Over half of the studies included in this analysis described state-wide interventions or 
interventions covering a region within a state. Four of the state studies examined hospital-
based programs; three were multi-state programs. 
In addition to differing in their scope, the guideline implementation programs also 
differed in their overall components. The most common component was general data-feedback 
which was present in over 70% of the implementation programs. General data feedback about 
hospital performance was either made available to individual physicians or public disseminated 
in routine meetings. The other common components of the guideline implementation programs 
included standing order sets, educational programs, and computerized decision support 
systems. The least common components of successful programs were the use of 
multidisciplinary teams and rewards or recognitions for guideline-adherent physicians. A 
detailed list of each variable and their prevalence among the overall and successful guideline 
implementation programs can be see in Table 3. 
Certain variables seemed to be more common than were others in successful programs. 
All but one of the statistically significant studies demonstrated some form of data feedback. In 
some programs, such as the one described by Berthiaume, Davis, and Tiara, data feedback 
about national, statewide, peer-group averages was distributed to all physician in the form of 
quarterly reportsa•. 4345 LaBresh et al. and Zhang et al. described rapid-cycle data feedback that 
could be accessed by physicians at any time46· 47 
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Clinical education is another component correlated with success and was present in four 
out of the six programs with statistically significant improvements. (Table 3) Clinical education 
for most programs involved providing health care providers with information about the most 
recent clinical practice guidelines and to which patients those guideline apply. Some clinical 
education was delivered face-to-face 44· 48· 49, while others were delivered in the form of a 
newsletter 39· 43 . Neither face-to-face or newsletter seemed to be equally effective at predicting 
program success. 
Clinical pathways and clinical care coordinators were also more common among 
programs with statistically significant improvement. Unlike general data feedback and education 
components, there was little variation in the way clinical pathways and care coordinators were 
implemented in the guideline implementation programs. Clinical pathways were presented 
through either the computer system or in paper form depending on whether how the hospital 
placed its medication orders. In each of program care coordinators were in charge of following 
guideline appropriate patients and issuing reminders to their physicians. 
Discussion 
The goal of this analysis of the guideline implementation literature was to evaluate 
whether guideline implementation programs have been effective at increasing guideline 
adherence, and if so, what specific components are responsible for their success. Not only does 
this paper shed light on the components that make guideline implementation programs 
successful, it also reveals which programs appear to be successful at which kind of adherence 
improvement. 
Overall the results of this analysis demonstrate that guideline implementation programs 
can be effective at increasing the rate at which physicians write beta-blocker prescriptions for 
post-MI patients. Out of the 15 articles included in this study, six programs demonstrated 
statically significant improvements in guideline use. Although many factors no doubt contribute 
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to program success, some trends are particularly notable. The studies that demonstrated the 
strongest success tended to be large multi-state programs with large sample sizes - making 
significance easier to demonstrate -- and certain program components -that may be genuine 
indicators of what works. 
The factors most strongly correlated with success were the use of general data feedback 
and clinician educational programs. These components were the most common variables 
among the statistically significant guideline implementation programs, yet, it is difficult to 
determine if these components are the reason for success; institutions who are disposed to form 
multidisciplinary teams and provide clinician education might, with all things being the same, be 
more likely to use guidelines, multidisciplinary teams and educational programs were also 
common in programs that were less successful. It does, however, seem reasonable to suggest 
that both team formation and education would be good strategies for guideline adoption. 
What do the results mean? 
This analysis suggests that certain variables are associated with success in all programs 
but some variables work better in certain types of programs, and not in others. In general, most 
programs seem to benefit from the presence of clinical care coordinators. The clinical care 
coordinator is someone who tracks all of the patients within the health care system and 
identifies the patients to whom the guideline applies. He or she also makes sure that those 
patients receive recommended care and that their physicians are aware of the guidelines. The 
presence of clinical care coordinators does not assure that every patient will receive evidence-
based care. Instead, they prevent guideline-appropriate patients from slipping through the 
cracks by reminding physicians of the patients to whom the guideline applies, and giving them 
the discretion to decide whether the guideline is appropriate to that patient. Although the clinical 
care coordinator is only present in about a third of all the evaluated programs, they are present 
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in half the programs with significant levels of success. Clinical care coordinators may facilitate 
the deployment of guideline recommendations to the right patient at the right time. 
Clinical educational initiatives also seem to be indicative of success in most guideline 
implementation programs. Four out of the six statistically significant studies had some sort of 
clinical education initiative. Even if the guideline implementation programs are not capable of 
providing a wide variety of components, education initiatives have been shown to be one of the 
strongest influences on guideline adherence. 50 This study and other interventions like it seem to 
suggest that making sure clinicians are aware of existing guidelines, even without the 
supplemental program components, may be enough to improve guideline adherence. 
Although statistical significance is often the primary way of measuring program success, 
we must not lose sight of the importance of clinical significance, particularly as small program 
evaluations may lack statistical power to show the statistical significance even of meaningful 
change. Most of these programs appear to have demonstrated quality improvements even 
without associated statistical significance. Determining what makes a result clinically significant 
can depend on factors such as the magnitude of the result, the burden of the disease in 
question, and the cost-effectiveness of the intervention. Ultimately, clinical signficance has to be 
determined by the providers who are delivering the care. 
Different types of programs 
This analysis has also shed light on the variety of implementation programs and the 
components that might be most important to them. One structural factor distinguishing different 
types of guideline implementation programs is the scope of the intended change. This study 
found three distinct programs differing according to the number of people they are targeted to 
reach. The smallest scope of intervention included in this study is the hospital-based programs. 
The largest interventions were simultaneous multi-state programs. In between hospital based 
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and multi-state interventions were state-wide programs implemented throughout the entire 
states or portions of states. 
Aside from differing in the number of people the programs reach, the scope of an 
intervention may also be an indicator of its effectiveness. In this analysis, the large-scale 
interventions were more likely to be statistically significant than the smaller hospital-based 
programs at least partly for structural and size reasons. All three of the multi-state interventions 
had statistically significant results. 47· 51 · 52 Of the four small hospital-based interventions, only one 
showed statistical significance. 53 Of the eight state-wide interventions, only two demonstrated 
statistical significance.43· 44 A more detailed description of these the studies and there results 
can be found in the evidence table, Table 1. 
This example of varying significance may be a simple artifact of larger Ns of cases, since 
all studies with Ns of 3000 or more were significant. Studies with larger sample sizes are more 
likely to have statistically significant findings. It is also possible that broad, multistate guideline 
implementation efforts may represent intense desire for change at high levels. Simply 
undertaking to arrange a multistate intervention is itself a demonstration of the commitment to 
improve guideline adherence. In order to truly understand what is causing this phenomenon, a 
meta-analysis of program evaluation studies will need to be conducted. The increased statistical 
power offered by meta-analysis can help determine is the success of larger programs is a real 
association. 
One of the advantages to implementing smaller interventions, on the other hand, invokes 
what can be thought of as a physician factor: that is, small interventions can be tailored closely 
to fit local patient populations and care delivery circumstances, and the literature suggests that 
physicians are much more likely to welcome guidelines the development or adaptation of which 
they feel they have influenced so By design, guidelines are meant to be tailored and adapted as 
needed to fit different clinician and patient populations. Smaller interventions can address the 
specific concerns of health care systems in a way that larger programs may not. The 
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disadvantage of smaller interventions, as noted above, is that smallness can make success 
difficult to measure 
Another physician factor, physician education, seems to be an important component for 
any guideline implementation program. It seems to have greater significance for smaller 
programs. One of the strongest predictors of guideline adherence is awareness that the 
guideline exists. 50 The first step in implementing guidelines is making sure that the clinicians 
and patients to whom the guidelines apply are aware of the recommendations. Education 
components are especially important for smaller interventions because these programs often 
have limited access to resources for quality improvement and guideline implementation. 
Education is one of the less expensive program components, and it seems to be indicative of 
success. 
Structural variables such as health care coordinators and multidisciplinary teams, 
although shown to be effective when included in guideline implementation programs, typically 
require considerable resources, including hiring staff and enforcing changes in the delivery of 
care. Unlike these more expensive components, education initiatives can be effective at 
increasing guideline awareness and guideline adherence at relatively low cost. 
Another structural distinction between different types of programs is determined by the 
number of components included in an intervention. Because so many variables can be included 
in a program, the development of a new guideline implementation program often raises 
concerns about which components to include. Different components have different advantages, 
and it can be difficult to decide on narrow rather than broad approaches to change. 
This analysis suggests that the goal-specific approach to picking program components is 
particularly beneficial for hospital-based or small statewide programs, probably for "physician 
factor" reasons. The only hospital-based intervention with statistically significant results chose to 
focus completely on providing a comprehensive clinical pathway53 , and this local adaptation is 
the kind of physician-led effort that the literature says is necessary for physician acceptance of 
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guideline recommendations. If a hospital has many other components already in place but only 
lacks one potentially beneficial variable, it is better to add the missing component than to try 
broader change, potentially exhausting resources and diffusing energy. 
In contrast, larger multi-state interventions seem to work better if they are broad 
multifactorial programs. Because larger statewide programs and multi-state programs usually 
have infrastructure and resources, they can afford to invest in a wide variety of components. By 
their very nature, state-wide programs and multi-state programs are dealing with a variety of 
health care systems; this diversity of systems may mean that a broad program, with many 
features, has a better chance of hitting the target of better adherence in different contexts. For 
example, within the same statewide program, one hospital may already be meeting most 
guidelines and providing many of the components important to guideline implementation; such a 
system may need comparatively few new elements in order to achieve further success. In the 
same statewide program, small community hospitals with limited resources may have difficulty 
establishing guideline adherence. Programs capable of delivering many different components 
can address both kinds of system needs. 
What is contributing to the results? 
It is possible that the relationship between the scope of an intervention and its 
effectiveness has more to do with the sample size of the study. The articles evaluating multi-
state interventions tended to have larger number of participants, whereas hospital-based and 
state-wide interventions tended to have smaller sample sizes. The likelihood that a study will 
demonstrate statistical significance is fundamentally determined by the sample size and 
statistical power of that study. This means that the effectiveness of multi-state interventions 
might not have had anything to do with the scope of the intervention, although, as noted, the 
sheer effort required to create a large intervention itself demonstrates commitment to success. 
Another sucees factor, probably interacting between physician and structural considerations, is 
33 
the baseline adherence rate at the time of the intervention. Clearly, floor and ceiling effects are 
at work: programs with baseline adherence rates of less than 80% were more likely to have 
statistically significant results because they had more room in which to move. Ceiling effects 
need to be kept in mind when evaluating the potential for further change of already high-
performing systems. 
The importance of patient outcomes 
Identifying the best candidates to improve patient outcomes is the point of this analysis. 
If guideline implementation programs are not effective at improving patient outcomes then there 
is really no point in applying them. In the case of beta-blockers and Ml, the patient outcomes of 
interest are mortality and morbidities such as repeat Mls or heart failure. Even though studies 
have suggested that guideline implementation programs can increase beta-blocker use and the 
medical literature has demonstrated that beta-blockers are effective at reducing morbidity and 
mortality in Ml patients, we need studies that demonstrate the vital connections between 
guideline adherence and better outcomes for patients. 
It is possible that a guideline implementation program that is successful at improving 
quality indicators such as beta-blocker prescriptions may only have a modest effect on health 
care outcomes such as mortality or repeat MI. It is important that program evaluation studies 
evaluate patient outcomes in addition to quality indicators. In the larger scheme of health care, it 
is not enough to know that guideline implementation are improving guideline adherence, but that 
those programs are improving health care in general. 
Cost effectiveness 
We should consider cost effectiveness when we evaluate the implementation of any 
CPG program. Although most people today assume that evidence-based medicine has had a 
significant effect on improving certain aspects of health care quality, it is also clear that 
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evidence-based medicine has yet to reach its full potential and still has quite a bit of room to 
grow. Cost-effectiveness requires more attention in studies of guideline adherence than it 
usually receives. Programs not only have to be effective at improving patient outcomes, but 
they are usually expected to do so in economically sustainable ways. 
One of the common misconceptions about cost effectiveness is that improving the 
quality of health care will, ipso facto, reduce health care cost. Just because inefficient health 
care often wastes money, however, it does not mean improving that health care system will 
necessarily save money. In fact, the opposite is often true. Improving health care on systems 
levels may well require significant resources. Hiring new staff, implementing systems changes, 
and maintaining those efforts not only requires a great deal of effort but also a large amount of 
money. 
I think that money, or the fear that money will have to be spent, has been one of the 
greatest obstacles to the translation of evidence into clinical practice. Systemic reviews and 
guidelines are available for areas of medicine with strong scientific evidence, but developing the 
tools needed to support these recommendations may require money that is often not available 
(small hospitals and private practices, for example, may lack the resources to adopt Health 
Information Technology, as so many guidelines recommend). 
Instead of a focusing strictly on saving money, health care systems should look at 
guideline implementation programs and other evidence-based medicine tools as an opportunity 
to spend money more efficiently. Instead of devoting resources to efforts that do not have 
evidence of effectiveness, it makes more sense to find out what is working and spend energy 
doing that. Studies like the present work are important because they help determine whether 
resources are being used well, and suggest how they can be used better. If we see that certain 
guideline implementation program are more effective than others, this will help health care 
systems, especially those under tight fiscal constraints, spend their resources in the most 
effective manner. 
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Should programs be optional or required? 
In the hustle and bustle of an inpatient course or outpatient clinic, failure to implement 
guidelines in appropriate patients may have more to do with time constraints and momentary 
forgetfulness than blatant disregard for the medical literature. As a result, many of the 
components that are common among guideline implementation programs have been set in 
place to address these obstacles. The question is whether program components such as clinical 
pathways and reminder forms should be optional or required. 
While components of guideline implementation programs like reminder forms and data 
feedback are helpful, they are often not adapted in a way that matches with the evidence that 
spawned them. If the evidence is strong enough to warrant guideline recommendation, it is likely 
also strong to warrant making these tools a vital part of that health care system. Instead of 
making reminder forms available in such a way that clinicians have to remember to use them, 
why not make these reminder forms the default system? 
Most optional guideline implementation programs leave much to the discretion of the 
practitioner. The way most such programs are designed, even helpful tools, by being "optional," 
may not be readily available to clinicians. The downside to a completely optional program is 
that practitioners must make a conscious effort to seek out these programs in order to use them. 
In contrast, programs with "required" components are incorporated into the existing health care 
system as the defaults. 
When most programs are implemented, their features are not often fully integrated into 
the existing system of care. Although research evidence will never apply to all patients, in areas 
of medicine where there is strong clinical practice guideline those recommendations will likely 
apply to most of them. Therefore, it makes sense to make guideline implementation programs 
and their components the standard within the health care system, rather than an addendum that 
practitioners must seek out. For example, beta-blockers are recommended for about 80% of 
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post-MI patients. 38 Given the strength of the evidence, post-MI beta-blocker use should 
become the default standard of care. 
Should we move on to larger results generated by national programs? 
The results from this analysis suggest that larger programs tend to be more successful 
at improving guideline adherence than are smaller programs. If this is the case, is it safe to say 
that a national program will have the greatest efficacy? In this case, a national effort to make 
post-MI beta-blocker prescriptions for all appropriate patients may be a very effective strategy to 
change the standard of care. Theoretically, even small health care systems should be able to 
adopt this strategy, particularly if those small systems know that adoption meets a national 
standard. 
Limitations 
Even though the topic of post-MI beta-blocker use has been extensively studied when 
compared to other guideline recommendations, the number of studies is still limited, and the 
small number of program evaluation studies means that interpretation of results can be difficult. 
Surely, continued study of what makes guideline implementation most successful is warranted. 
Future studies 
This analysis has the potential to improve the development of future guideline 
implementation programs and influence how these programs are evaluated. In the future, 
studies must be conducted with enough statistical power to detect a statistically significant effect 
of different interventions. Many of the studies looking at the effectiveness of guideline 
implementation programs are analyzing pilot studies with few subjects. 
If the goal of these programs is to improve the translation of guidelines into clinical 
practice, effectiveness studies should be conduced in populations that reflect the health care 
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systems that need the programs. Many of the evaluation studies are conducted in health care 
systems with guideline adherence rates that were already well above the national average. 
While it may be argued that even hospitals with high beta-blocker prescription rates need 
incentive to improve their rates, the issue of selecting appropriate study populations still needs 
to be considered. 
Not only does the baseline rate of guideline adherence affect the ability demonstrate 
statistically significant improvement, results from studies done in hospitals with high guideline 
adherence rates may be difficult to replicate in settings with lower adherence rates at the outset. 
Further, initiating change may require different strategies than does sustaining the change one 
has initiated. Finally, change for one patient population may not achieve the same kind of 
change in systems with different populations. Future studies need to give considerable 
attention to the context in which change is desired. 
Conclusion: Looking Forward 
As health care systems attempt to find the most effective way to improve guideline 
adherence, patient adherence should also be explored. Evidence-based practice requires that 
physicians provide care supported by best evidence, but patients must also be receptive to that 
care and adhere accordingly. This involves finding ways to increase health literacy and improve 
access to treatments. Although these are complicated issues they are worth thinking about 
because many of these components can be incorporated in guideline implementation programs. 
Some of the programs analyzed in this study had components that also included patient 
education devoted to improving patient compliance with beta-blocker use. They measured 
patient response by recording how many of the beta-blocker prescriptions had been filled by 
patients. Although patient adherence to therapy is a separate issue from physician adherence to 
guideline recommendations, they work hand in hand in the translation of evidence into clinical 
practice. Both are necessary if any health care benefits are going to be seen. 
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Appendix. Variables Indicative of a Successful Implementation Program 
• Physician/Opinion Leaders 
0 = No Opinion Leader 
1 =Unofficial Leader (present but not part of intervention) 
2 = Official Leader (present and part of intervention) 
• Standing Order Sets 
0 = Not Available 
1 =Available but optional 
2 =Available and mandatory 
• Data Feedback 
0 = Not collected 
1 = Collected but not discussed 
2 = Collected and discussed in regular meetings 
3 = Collected and made public for hospital staff 
• Clinical Pathways 
0 = Not Available 
1 =Available but optional 
2 = Available and mandatory 
• Organizational Support For Quality Improvement (Health care system that provides 
adequate resources for projects, support from administration, physicians and nurses) 
0 = No organizational support 
1 = Minimal organizational support 
2 = Adequate organizational support 
• Educational Programs 
0 =No 
1 =Yes, Optional 
2 =Yes, Mandatory with intervention 
• Multidisciplinary Quality Teams 
0 =No 
1 =Yes 




• Computer Support Systems 
0 =No 
1 =Yes 
• Reminder Forms 
0 =No 
1 =Yes 
• Recognition and Rewards For Successful Efforts 
0 = No Recognition 
1 = Private Recognition 
2 = Public Recognition 
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Table 1. Evidence Table 
Study Study No. of Scope of Definition of Ml Length Demographics 
Design patients intervention of Study (Age/Sex) 
(Location) 
Bailey, 2007 RCT 853 Hospital-level Troponin > 1.4 4 months Age: 
(Barnes Jewish ng/mL • <55 y- 22.7% 
Hospital) • 55-66 y- 29.1% 
• >67 y- 48.2% 
Sex: 40% Women 
Berthiaume, Before-after 25,801 Statewide (Hawaii) 2 diagnoses of Ml, 4 years Age: 
2007 CAD or documented • <40 y- 2% 
CABG • 40-64 y- 56.8% 
• >65 y- 41.2% 
Sex: 33.6% Women 
Biviano, 2004 Before-after 292 Hospital-level ED patients w/ 1 year Age: mean age- 68 y 
(NY Presbyterian) trop.> 2.0 nq/ml Sex: 65.5% Women 
Butler, 2006 Before-after 576 Hospital-level ICD-9 code for Ml 2 years Unknown 
(Vanderbilt 
Hospital) 
Fonarow, 2001 Before-after 558 Hospital-level Medical record 4 years Age: mean age - 70 y 
(UCLA) diagnosis of Ml Sex: 42% Women 
Hilbert, 2000 Before-after 400 Statewide (TX) Medical record 3 months Unknown 
diaqnosis of Ml 
LaBresh, 2004 Before-after 1,738 Statewide (MA) Not specified 1 year Unknown 
Lappe, 2004 Before-after 57,465 Statewide (UT) Medical record 6 years Age: mean age - 66 y 
diagnosis of Ml Sex: 42.3% Women 
Marciniak, 1998 Before-after 12,339 Multi-state Medicare pts 4 years Age: mean age - 75 y 
(AL,CT, lA, WI) discharged w/ Ml Sex: 48% Women 
Mehta, 2002 Combo 1,649 Statewide (MI) Discharge ICD-9 1 year Age: mean age - 73 y 
code for Ml Sex: 47.9% Women 
Mehta, 2004 Before-After 1,022 Statewide (MI) Medical record 1 year Age: mean age - 67 y 
diagnosis of Ml Sex: 43.3 %Women 
Rammuno, Before-After 350 Multi-state Discharge diagnosis 3 years Unknown 
1998 (ME,NH,VT) ofMI 
Sauaia, 2000 Combo 1,367 Statewide (CO) Discharge diagnosis 2 years Age: mean age = 7 4 y 
ofMI Sex: 43% Women 
Zhang, 2005 Before-After 11,394 Multi-state Discharge diagnosis 1 year Age: mean age - 70 y 
(CA, LA, FL) ofMI Sex: 40% Women 
Zuckerman, Before-After 2284 Statewide (PA) Medicaid patients 1 year Age: 
2004 with a medical • <50 y-11% 
record diagnosis of • 50-69 y -40% 
Ml • >70 y- 49% 
Sex: 63.8% women 
• the p value refers to comparison of the follow-up values (after implementation) between the control and intervention groups 
The unit of analysis for all of the above studies is the patient. All randomizations were at the level of the patient. 
Outcome Results P-value 
(control vs. intervention) RCT 
(before to after) before-after 
91.8% vs. 95.9% p- 0.08 
36% to 47% p < 0.001 
89% vs. 94% p- 0.45 
88% to 95% p- 0.07 
12%to61% p < 0.01 
57.5% to 74.3% Unknown 
85% to 84% p > 0.05 
53% to 91% p < 0.001 
31.8% to 49.7% p < 0.001 
70.3% to 86.4% (control) p - 0.27' 
87.3% to 92.9% (intervent.) 
78.4% to 90.4% p- 0.075 
69.1% to 82% p < 0.01 
65% to 88% (control) P-0.47' 
48% to 73% (intervent.) 
62.4% to 83.5% p < 0.001 
46.3% to 49.6% (7 day p- 0.13 
analysis) p = 0.12 
61% to 64.7% (30 day 
analysis) 
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Table 2. Brief Study Description 
Study Brief Description 
Bailey, 2007 A randomized prospective study conducted between 02/01 and 05/01 in St. Louis, MO at Washington University. It was a hospital level 
intervention done within one university-teaching hospital. The intervention included a computer support system that flags eligible patients and a 
care coordinator contacted physicians (by phone or face-to-face) about eligible patients who were not receiving evidence-based health care. 
Berthiaume, 2007 A retrospective observational analysis (before-after study) conducted between 2000 and 2004 in Hawaii. It was a statewide intervention 
conducted on patients enrolled in Hawaii Medical Service Association (HMSA), an independent licenser of BCBS. All patients were diagnosed 
with CAD or CABG/PTCA. The intervention included education for physicians via newsletter, medication reports, and CME credit; 
flowsheets/pathway, case manager, pay-for-performance, and general data feedback reports. 
Biviano, 2004 This is a before-after hospital-level study conducted between 2000 and 2001 in NY Presbyterian Hospital. All patients presented with troponin > 
2.0 ng/mL within 24 hours. The preprotocol group was comprised of patients evaluated before the intervention. The protocol group was divided 
into control (where the intervention was used) and the intervention group (where the intervention was not used. The intervention included 
educational sessions for house staff physicians, clinical pathways, and clinical care coordinators. 
Butler, 2006 A before-after study conducted between 7/01 and 6/02 at Vanderbilt University. The intervention included a computer system that flags patients 
with AMI before they are discharged to give them a reminder about standard AMI care. Use of the program increased from 7% to 52% throughout 
the intervention. 
Fonarow, 2001 A before-after study conducted between 1992-1995 in a university/teaching hospital. Participants had documented CAD (256 pre-CHAMP and 
302 post-CHAMP). The intervention for the Cardiac Hospital Atherosclerosis Management Program (CHAMP) and included a treatment algorithm 
(clinical pathway to make sure that beta-blocker therapy was started on all patients with AMI or UA 
Hilbert, 2000 A before-after trial conducted between 1999 and 2000 throughout Texas. Baseline measures were collected using self-chart audit and followed at 
3 months, 6 months, and 12 months. This was a multifaceted interactive statewide intervention with Texas Health Care Partnership (HCP). Each 
hospital looked at 50 charts and each physician practice looked at 30 charts. The comprehensive intervention included an education program, 
consensus development about quality improvement process, and development of patient education tools. Data feedback was also provided. 
LaBresh, 2004 A before-after study was conducted between 07/00 to 06/01 in 24 Massachusetts hospital. From. It was a state level intervention. There were 
1738 patient with CAD and AMI. The intervention for the Get With The Guidelines program included physician leaders, hospital teams, reminder 
screens, data collection with real time feedback, printed order sets, discharge forms and web-based management. 
Lappe, 2004 A before-after study conducted between 1996 and 2002 and based in Utah. It was a state-based intervention in the 10 largest hospitals in Utah 
associated with Intermountain Health Care- a non-profit health care system. The "discharge medication program" was a multi-hospital integrated 
system that included an institution-wide database with monthly feedback meetings, extensive education campaigns, patient discharge forms, care 
coordinators (die planning nurse), computerized system to track discharge medications. 
Marciniak, 1998 A before-after study conducted between 1992 and 1995 in various states (Alabama, Connecticut, Iowa, Wisconsin). All participants were 
Medicaid patients diagnosed with AMI on discharge. The Cooperative Cardiovascular Project included education efforts, PRO physicians leaders, 
and data feedback presented by PROs, telephone, mailings. They also offered recommendations for standing orders and clinical pathways. 
Mehta, 2002 This is a before-after/control study of the Southeast Michigan. Between July 1998 and July 1999. The intervention included AMI standard orders 
sets, clinical pathways, pocket guides for AMI, patient information, discharge forms, chart stickers, hospital performance charts, standard orders, 
and educational support. 
Mehta, 2004 This is a before-after study conducted from 01/01 to 03/02 conducted in Flint and Saginaw Michigan expansion. The intervention included AMI 
standard orders sets, clinical pathways, pocket guides for AMI, patient information, discharge forms, chart stickers, hospital performance charts, 
standard orders, and educational support. 
Rammuno, 1998 A before-after study conducted between 1994 and 1997 in various states in northern New England. Cooperative Care Project. All participants 
had confirmed AMI diagnosis at hospital discharge (217 participants in the before group and 133 in the after group). The Cooperative 
Cardiovascular Project included data feedback mailed to physicians with hospital-specific, state-wide, and peer group data. It also in~~ded new 
action plans for improvement. 
Table 2. cont. 
Study Brief Description 
Sauaia, 2000 A randomized control trial conducted in Colorado. Included 18 hospitals (10 rural and 8 urban) that were randomized to the Coopertaive 
Cardiovascular intervention or standard written feedback. All participants were diagnosed with AMI when discharged from the hospital. The 
intervention included on-site presentation by a physician leader that provided feedback about individual physician performance in comparison 
to state and national averages. Hospitals were also encouraged to organize multidisciplinary quality teams and include them in the groups. 
Zhang,2005 A before-after study conducted between 01/01 and 06/02 in multiple sites throughout the nation (Southern California, New Orleans, and 
South Florida). It was conducted in hospitals owned by the Tenet Healthcare Corporation. There were 11,394 patients included in the study 
who were diagnosed with AMI and discharged from the hospital. The intervention included a rapid cycle computer data feedback, process 
improvement teams (senior management, director, case management team, quality department and clinicians), case managers, and internal 
reportinq website. 
Zuckerman, 2004 This is a before-after study conducted in Pennsylvania. Done between 11/98 and 11/99. It was done state-wide with physicians of the 
Pennsylvania Medical Society. The intervention included identifying physicians with less than 80% beta-blocker prescription rates and 
providing them with educational material (by mail for CME credit) and Medicaid patient feedback. This study evaluated patients at 7 days and 
30 days post-MI. 
Table 3. Program Components 
Percentage of all of studies Percentage of successful programs 
Physician/Opinion Larders 4/15 (27%) 1/6 17%) 
Standing Order Sets 7/15 47%) 3/6 50% 
Gen. Data Feedback 11/15 73%} 5/6 83% 
Clinical Pathways 6/15 40%) 3/6 (50% 
Organizational Support 6/15 40% 1/6 17%) 
Education Programs 7/15 47% 4/6 67%} 
Multidisciplinary Teams 3/15 20% 1/6 17%} 
Care Coordinators 6/15 40% 3/6 150%) 
Computer Support 7/15 47% 2/6 (33%} 
Reminder Forms 4/15 (27% 0/6 (0%) 
Recognition/Rewards 1/1517%) 1/6117%) 
Discharge Form 4/15 (27% 1/6 17%} 
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